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AMENDING TRIPS: A NEW HOPE FOR 
INCREASED ACCESS TO ESSENTIAL 
MEDICINES 
INTRODUCTION 
lobal health has been a central concern of the international com-
munity since the creation of the United Nations.1 Despite focused 
efforts by governments, regional and international alliances, and non-
governmental organizations (“NGOs”),2 a variety of obstacles continue 
to thwart the attainment of acceptable health standards across the globe.3 
                                                                                                             
 1. For example, in 1948, the United Nations created a special agency, the World 
Health Organization (“WHO”), devoted to working towards attaining the highest possible 
standard of health for all peoples in the world. Over 190 countries participate in setting 
international health policy and implementing programs aimed at achieving the WHO 
mandate. WHO, Governance of WHO, http://www.who.int/about/governance/en/index 
.html (last visited Jan. 18, 2008). Since the creation of the WHO, the international com-
munity has continually reiterated its commitment to world health by creating other or-
ganizations and programs to deal with health issues on a global scale, such as the United 
Nations Children’s Fund (“UNICEF”), the United Nations Population Fund (“UNFPA”), 
and the Joint United Nations Program on HIV/AIDS (“UNAIDS”). YVES BEIGBEDER, 
INTERNATIONAL PUBLIC HEALTH 3 (2004). International commitment to world health is 
further illustrated by the fact that non-health related entities such as the World Bank and 
the World Trade Organization (“WTO”) now play a major role in financing and formulat-
ing health policy. Id. at 4–5. 
 2. For example, in 2003, the administration of United States President George W. 
Bush launched the President’s Emergency Plan for AIDS Relief (“PEPFAR”), “a five-
year, $15 billion, multifaceted approach to combating the disease around the world.” See 
The Office of the U.S. Global AIDS Coordinator, About PEPFAR, http://www.pep 
far.gov/about/ (last visited Feb. 24, 2008). In 2001, various Caribbean heads of state cre-
ated The Pan Caribbean Partnership on HIV/AIDS (“PANCAP”), a coalition of public 
and private national, regional, and international organizations charged with scaling up 
national and regional responses to HIV/AIDS in the Caribbean. See PANCAP, 
http://www.pancap.org/index.php (last visited Jan. 18, 2008). In 1972, a coalition of 
“NGOs, foundations, corporations, government agencies and academic institutions” 
joined together and formed the Global Health Council, whose mission is “to ensure that 
all who strive for improvement and equity in global health have the information and re-
sources they need to succeed.” See Global Health Council, Who we Are, 
http://www.globalhealth.org/view_top.php3?id=25 (last visited Feb. 24, 2008). 
 3. These include structural and societal challenges such as severe shortages of health 
workers in poor countries. See generally World Health Organization, The World Health 
Report 2006—Working Together for Health (2006), available at http://www.who.int/wh 
r/2006/whr06_en.pdf. On lack of access to basic sanitation and safe drinking water, see 
generally World Health Organization, Meeting the MDG Drinking-water and Sanitation 
Target (2006), available at http://www.who.int/water_sanitation_health/monitoring/jmp 
final.pdf. Regarding inadequate research into certain diseases that are prominent but for 
which there is no commercial market, see Special Rapporteur of the Commission on Hu-
man Rights on the Right of Everyone to the Enjoyment of the Highest Attainable Stan-
G 
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One such obstacle in the fight against HIV/AIDS4 is inadequate access to 
essential medicines5 in low- and middle-income countries.6 According to 
a recent World Health Organization (“WHO”) study, eighty percent of 
HIV/AIDS patients that live in low- and middle-income countries and are 
in need of essential antiretroviral drug therapies7 do not have access to 
                                                                                                             
dard of Physical and Mental Health, Mission to the World Trade Organization, ¶ 44, U.N. 
Doc E/CN.4/2004/49/Add.1 (Mar. 1, 2004) [hereinafter Special Rapporteur’s Mission to 
the WTO]. There are also cultural challenges such as the stigma and violence faced by 
HIV positive persons that prevent many from getting tested or admitting that they are 
positive. See Tina Rosenberg, When a Pill Is Not Enough, N.Y. TIMES, Aug. 6, 2006, § 6 
(Magazine), at 41 (describing some cultural obstacles to AIDS prevention in Africa). In 
2003, the Bill and Melinda Gates Foundation, in collaboration with others, compiled a list 
of scientific and technological “grand challenges in global health” that included improv-
ing nutrition, insect, control, and vaccine delivery systems. See H. Varmus et al., Grand 
Challenges in Global Health, 302 SCIENCE 398, 399 (2003). 
 4. HIV, which stands for human immunodeficiency virus, is a human retrovirus that 
impairs the immune system over time as it replicates itself in the body. Pablo Tebas & 
Mary Horgan, The Immuno-Compromised Host, in THE WASHINGTON MANUAL OF 
MEDICAL THERAPEUTICS 288–89 (Charles F. Carey et al. eds., 29th ed. 1998). Eventually, 
the condition leads to AIDS, the acquired immune deficiency syndrome. Id. In the final 
stage of AIDS, known as full blown AIDS, “immune defenses break down completely 
and secondary (opportunistic) diseases attack the body. . . . Death usually follows a few 
years later.” AM. JUR., PROOF OF FACTS: ATTORNEY’S ILLUSTRATED MEDICAL DICTIONARY 
at A22 (3d series, 2002). In 2006, a total of 39.5 million people were living with HIV 
globally and there were 2.9 million AIDS-related deaths. Joint United Nations Pro-
gramme on HIV/AIDS [UNAIDS] & World Health Organization [WHO], AIDS Epi-
demic Update, at 3, U.N. Doc. UNAIDS/06.29E (Dec. 2006), available at 
http://www.who.int/hiv/mediacentre/2006_EpiUpdate_en.pdf. Sixty-three percent of the 
world’s HIV positive population lives in sub-Saharan Africa and thirty-four percent of 
the 2006 AIDS-related deaths occurred in southern Africa. Id. 
 5. Essential medicines are those that, according to the WHO, “satisfy the priority 
health care needs of the population. They are selected [by the WHO] with due regard to 
public health relevance, evidence on efficacy and safety, and comparative cost-
effectiveness.” Essential Medicines, http://www.who.int/topics/essential_medicines/en/ 
(last visited Jan. 18, 2008). The updated WHO essential medicines list is available  
at http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf 
(last visited Jan. 18, 2008). 
 6. See generally WHO, Progress on Global Access to HIV Antiretroviral Therapy: A 
Report on “3 by 5” and Beyond (March 2006) [hereinafter 3 by 5 Report], available at 
whqlibdoc.who.int/publications/2006/9241594136_eng.pdf (reporting that the goal of a 
joint WHO and UNAIDS initiative aimed at providing treatment to 3 million AIDS pa-
tients by 2005 had not been met and that treatment levels continue to be a major con-
cern). See also infra Part I.A. 
 7. Antiretroviral treatments “temporarily suppress viral replication and improve 
symptoms” in HIV patients. WHO, Essential Medicines, § 6.4.2 (14th ed. Mar. 2005), 
available at http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf. When used in the appro-
priate combination, they are the most effective means of suppressing HIV replication, 
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them.8 There are a number of factors responsible for the staggeringly low 
rate of access.9 One major culprit is drug prices.10 The simple fact is that 
millions across the globe continue to suffer despite the existence of med-
ical technology to improve their lives because they or their governments 
cannot afford to pay for treatment.11 
Drug prices are set by the pharmaceutical companies that have invested 
time and money into the research and development that leads to medical 
discoveries.12 In order to make the investment worthwhile and recoup 
their expenses, these companies patent their ideas. The patents give them 
the power to exclude others, namely generic manufacturers, from cheap-
ly producing and profiting from their inventions.13 Recognizing that 
without the ability to patent, and therefore profit from, their intellectual 
property, companies would cease the research necessary to discover 
medical technology, international trade regimes seek to ensure that 
pharmaceutical patents are honored across the globe rather than only in 
the companies’ home countries.14 The primary instrument for enforcing 
global patent protection is the Agreement on Trade-Related Aspects of 
                                                                                                             
Tebas & Horgan, supra note 4, at 290, and they are considered an essential component of 
HIV/AIDS treatment, Essential Medicines, supra. Their critical importance in combating 
the HIV/AIDS epidemic was underscored in 2003 when the United Nations launched a 
massive initiative called “3 by 5” to scale up global access to antiretroviral treatment. See 
supra note 6. 
 8. See World Health Organization, World Health Statistics 2006, at 18 (2006) [here-
inafter WHO Health Statistics], available at http://www.who.int/whosis/whostat2006/en 
/index.html. 
 9. These include challenges associated with “partnerships, alignment, and harmoni-
zation; sustainable financing; drugs and other commodities; constraints in health systems, 
including human resources; ensuring equitable access; and monitoring, evaluation and 
research.” 3 by 5 Report, supra note 6, at 55. 
 10. See, e.g., Special Rapporteur’s Mission to the WTO, supra note 3, at 12. 
 11. See, e.g., id. 
 12. Cf. ROBERT P. MERGES, PETER S. MENELL & MARK A. LEMLEY, INTELLECTUAL 
PROPERTY IN THE NEW TECHNOLOGICAL AGE 119 (3d ed. 2003) (explaining that under the 
“economic incentive” theory of patent law, “absent patent protection, inventors will not 
have sufficient incentive to invest in creating, developing, and marketing new products” 
and that patent protection allows “the inventor to appropriate the full economic rewards 
of her invention”). 
 13. Cf. id. at 113 (“A patent confers the right to exclude others from making, using, 
selling, offering for sale, or importing the claimed invention for a specific term of 
years.”). For a brief overview of the patent system, see Craig J. Madson, Patents, in THE 
INTELLECTUAL PROPERTY HANDBOOK 229–60 (William A Finkelstein & James R. Simms 
III eds., 2005). 
 14. See, e.g., Agreement on Trade-Related Aspects of Intellectual Property Rights  
§ 5, Apr. 15, 1994, Marrakesh Agreement Establishing the World Trade Organization, 
Annex 1C, 33 I.L.M. 1197 (1994) [hereinafter TRIPS]. 
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Intellectual Property (“TRIPS”),15 which was promulgated by the World 
Trade Organization (“WTO”)16 in 1994 and has been ratified by all 193 
current member states.17 
International policymakers, however, have not been insensitive to the 
needs of sick, poor people in developing nations. TRIPS and subsequent 
WTO policy resolutions do allow countries to break patents under certain 
specified conditions when necessary to respond to emergencies such as a 
public health crisis.18 However, these provisions, which are commonly 
referred to as “flexibilities,”19 have not been successful in decreasing 
drug prices and thereby increasing access to essential medicines.20 This 
failure is due in large part to the fact that patent flexibilities set by the 
WTO have been undermined by bilateral and multilateral free trade 
agreements (“FTAs”), most prominently by those negotiated between the 
United States and developing nations.21 
                                                                                                             
 15. Id. 
 16. The WTO was created in 1995 to serve as an international institution that would 
carry out and promote the goals of the General Agreement on Trade and Tariffs 
(“GATT”). The GATT was originally negotiated in 1948 and served as both a provisional 
agreement and a provisional organization designed to promote international commerce by 
establishing a liberal world trade regime. Between 1948 and 1994, this was done primar-
ily through a series of negotiations known as trade rounds. The final trade round was the 
Uruguay Round, which lasted seven and one half years and included 123 countries. The 
Uruguay Round replaced GATT the organization with the WTO but maintained an up-
dated version of GATT the agreement as the main governing document. It also adopted a 
number of other agreements that established additional trade rules. These agreements are 
continually revised and renegotiated at ministerial conferences. See WTO, Understanding 
the WTO, 9, 14–22 (3d ed. 2005), available at http://www.wto.org/english/thewto_e 
/whatis_e/tif_e/understanding_e.pdf. 
 17. Margo A. Bagley, Legal Movements in Intellectual Property: TRIPS, Unilateral 
Action, Bilateral Agreements, and HIV/AIDS, 17 EMORY INT’L L. REV. 781, 782 (2003). 
 18. See TRIPS, supra note 14, art. 31; see also WTO, Doha Ministerial 2001: Decla-
ration on the TRIPS Agreement and Public Health, WT/MIN(01)/DEC/2, 41 I.L.M. 755 
(May 2002) [hereinafter Doha Public Health Declaration], available at 
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (explicitly 
asserting that TRIPS “does not and should not prevent Members from taking measures to 
protect public health” and clarifying the exceptions to the patent rules that governments 
may make for legitimate public health concerns). 
 19. WTO, Fact Sheet: TRIPS and Pharmaceutical Patents, http://www.wto.org 
/english/tratop_e/trips_e/factsheet_pharm02_e.htm (last visited Feb. 14, 2008). 
 20. See Bagley, supra note 17, at 791 (explaining that TRIPS flexibilities have been 
ineffective because they are rarely used). 
 21. See id. at 791–93; see also Margaret Chon, Intellectual Property and the Devel-
opment Divide, 27 CARDOZO L. REV. 2821, 2871 (2006); Maria Julia Oliva, Intellectual 
Property in the FTAA: Little Opportunity and Much Risk, 19 AM. U. INT’L L. REV. 45, 53 
(2003); cf. Michael D. Birnhack, Global Copyright, Local Speech, 24 CARDOZO ARTS & 
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Thus, lack of access to essential HIV/AIDS medicines because of unaf-
fordable drug prices continues to be a world health problem. However, 
this situation is more than a social tragedy; it also poses a legal dilemma. 
Access to medicine is a fundamental aspect of the right to health, secured 
for every person by the International Bill of Human Rights.22 On the oth-
er hand, not only do pharmaceutical companies also have intellectual 
property rights that must be protected,23 patent protection is necessary for 
the continued availability of drugs.24 The WTO has acknowledged these 
competing interests and has made significant progress towards reaching 
an appropriate balance.25 However, U.S. policy, as expressed in the 
pharmaceutical patent provisions of bilateral and multilateral FTAs, fails 
to adequately take the right to health into account. It secures significantly 
more stringent patent protection for pharmaceuticals than provided for in 
TRIPS without incorporating the necessary flexibilities that would enable 
increased access to medicines for health crisis situations.26 As such, it not 
only violates human rights norms, but also contradicts the WTO position. 
Thus, American policy must be changed. 
This Note attempts to contribute toward effecting such change by ex-
ploring mechanisms within the human rights and international trade 
realms for challenging patent provisions in U.S. FTAs. Part I establishes 
the practical need for change by describing the current lack of access to 
essential medicines in developing nations and the legal ramifications of 
inadequate access in the context of the international human right to 
health. Part II discusses the impact of WTO and American trade and in-
tellectual property polices on the accessibility of essential medicines. 
Part III argues that the WTO’s recent decision to amend TRIPS has two 
consequences that invalidate U.S. pharmaceutical patent policy. First, it 
                                                                                                             
ENT. L.J. 491, 513–14 (2006) (describing TRIPS-plus provision in U.S. and European 
multilateral agreements in the context of literary and artistic work). 
 22. See U.N. Econ. & Soc Council (“ECOSOC”), Comm. On Econ., Soc., & Cul. Rts 
(“CESCR”), Substantive Issues Arising in the Implementation of the International Cove-
nant On Economic, Social and Cultural Rights (General Comment No.14), ¶ 2, U.N. Doc. 
E/C.12/2000/4 (May 12, 2000) [hereinafter CESCR Gen. Comment 14], available at 
http://www.unhchr.ch/tbs/doc.nsf/(symbol)/E.C.12.2000.4.En?OpenDocument; see also 
infra part I.B. 
 23. See TRIPS, supra note 14; see also infra part I.C. 
 24. See supra notes 13–14. But see Special Rapporteur’s Mission to the WTO, supra 
note 3, ¶ 44 (pointing out that patent protection fails to incentivize medical research into 
diseases that only affect poor countries, such as river blindness and sleeping sickness, 
since the people that need such research would not be able to pay for it). 
 25. See supra note 18; see also Special Rapporteur’s Mission to the WTO, supra note 
3, ¶ 43; see also infra part II.A. 
 26. See supra note 21. 
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argues that the decision to amend, taken together with other historical 
developments, elevates the access to essential medicines component of 
the right to health to the status of customary international law. It then 
explores whether the amendment will invalidate U.S. policy as a viola-
tion of the General Agreement on Trades and Tariffs (“GATT”). Finally, 
The Note concludes with an assessment of the implications of these de-
velopments. 
I. THE NEED FOR CHANGE 
A. The Current Lack of Access 
Eighty percent of people in low- and middle-income countries that 
need antiretroviral therapy (“ART”) to treat HIV/AIDS do not have ac-
cess to it.27 Eighty-three percent of sub-Saharan Africans and ninety-five 
percent of northern Africans and Middle Easterners do not receive 
needed medicines.28 In East, South, and Southeast Asia, eighty-four per-
cent of those requiring ART do not receive it. In low- and middle-income 
countries in Europe and Central Asia, eighty-seven percent do not re-
ceive ART.29 In Latin America and the Caribbean, ART coverage is bet-
ter but still inadequate at sixty-eight percent.30 
While these statistics represent the situation in a substantial part of the 
world, they do not represent what the standard of care can be, especially 
considering that ART coverage in high-income countries, such as the 
United States, the United Kingdom, and France reaches above seventy-
five percent.31 Also disconcerting is the fact that access to treatment is 
uneven between similarly situated countries. For example, Thailand’s 
coverage reaches up to sixty percent32 while in India, ART is accessible 
to a mere seven percent of those that need it.33 Botswana and Uganda 
have over fifty percent coverage while coverage in other sub-Saharan 
countries is well below ten percent.34 
One reason why essential medicines are not reaching all who need 
them is their high price.35 Though prices have dropped over the last few 
                                                                                                             
 27. 3 by 5 Report, supra note 6, at 19. 
 28. Id. 
 29. Id. 
 30. Id. 
 31. WHO Health Statistics, supra note 8, at 37, 41. 
 32. Id. at 41. 
 33. Id. at 37. 
 34. 3 by 5 Report, supra note 6, at 7. 
 35. Id. at 29–30 (discussing drug prices in the context of access to HIV treatment and 
reporting statistics establishing an inverse correlation between treatment costs and num-
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years in some low-income countries, they remain “unacceptably high in 
some countries” and have remained “almost stable” in middle-income 
countries.36 Additionally, drugs that have decreased in price represent 
mostly first-line treatment37 while second-line treatment (used after pa-
tients develop immunities to first-line drugs38) costs are “prohibitive” in 
most countries39 and vary greatly amongst countries of similar income 
level.40 
Brazil, where ART coverage is at eighty-three percent,41 presents a 
prime example of the dramatic effect drug prices have on access to 
treatment. Brazil was the first developing nation to provide universal free 
AIDS treatment and has “the best anti-AIDS program of any developing 
country.”42 It has been able to afford this by manufacturing generic ver-
sions of brand name drugs, thus reducing costs by up to almost half.43 
Generic manufacturers have been identified favorably as contributing 
to the price drops that have occurred within the last few years.44 More-
over, in addition to making cheaper and therefore more accessible drugs, 
generic manufacturers are better able to serve the treatment needs of in-
dividuals in middle- and low-income countries because they provide 
                                                                                                             
ber of people treated in 2003, 2004, and 2005); Special Rapporteur’s Mission to the 
WTO, supra note 3, ¶ 43. 
 36. 3 by 5 Report, supra note 6, at 8. 
 37. Id. at 8–9 (reporting that in low-income countries the average cost per person per 
year of two particular types of first-line treatment ranged from $148 to $549 whereas a 
particular second-line regime cost an average of $1888). 
 38. First line treatment refers to a “preferred, standard, or first choice” drug or proce-
dure. Merriam-Webster Online Dictionary, http://www.merriam-webster.com/dictionary 
/first-line (last visited Feb. 28, 2008). 
 39. 3 by 5 Report, supra note 6, at 12. 
 40. Id. at 8–9 (reporting the cost of the same second-line treatment in the middle-
income Ivory Coast was $1700 but $6788 in its fellow middle-income country of El Sal-
vador). 
 41. Id. at 71. 
 42. Editorial, Brazil’s Right to Save Lives, N.Y. TIMES, June 23, 2005, at A18. 
 43. Brazil makes “copycat versions of expensive brand-name drugs” that were 
“commercialized before 1997, when the country began to respect patents on medicines, a 
requirement for joining the World Trade Organization.” Id. The system worked so well 
that in June 2005, Brazil became the first country to break the patent for a previously 
protected antiretroviral medicine when it announced that it would manufacture generic 
Kaletra. Todd Benson, Brazil to Copy AIDS Drug Made by Abbott, N.Y. TIMES, June 25, 
2005, at C12. Though WTO rules required Brazil to pay the patent holder, Abbott Labo-
ratories, a royalty on the generic version, the Brazilian government estimated that it 
would save $55 million per year. Id. 
 44. 3 by 5 Report, supra note 6, at 8. 
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drugs in therapy combinations not supplied by brand-name manufactur-
ers.45 
B. The Right to Health: Legal Ramifications of Inadequate Access 
That treatments for HIV/AIDS are available yet so many cannot access 
them is a great social tragedy. However, it is also a legal dilemma. On 
December 12, 1948, the General Assembly of the United Nations 
adopted the Universal Declaration of Human Rights (“UDHR”).46 From 
this list of principles emerged two binding treaties: the International Co-
venant on Civil and Political Rights (“ICCPR”)47 and the International 
Covenant on Economic, Social and Cultural Rights (“ICESCR”).48 These 
three documents together constitute the International Bill of Human 
Rights and have enabled the modern day human rights movement.49 They 
                                                                                                             
 45. 3 by 5 Report, supra note 6, at 60. 
 46. Universal Declaration of Human Rights, G.A. Res. 217A, at 71, U.N. GAOR, 3d 
Sess., 1st plen. mtg., U.N. Doc A/810 (Dec. 10, 1948) [hereinafter UDHR], available at 
http://www.unhchr.ch/udhr/lang/eng.pdf. As a declaration, the UDHR was intended to be 
“a moral and political influence on states rather than constitute a legally binding instru-
ment.” HENRY J. STEINER & PHILIP ALSTON, HUMAN RIGHTS IN CONTEXT 138 (2000). 
Nonetheless, it has had a tremendous impact on the development of international law: 
[I]t has retained a place of honor in the human rights movement. No other 
document has so caught the historical moment, achieved the same moral and 
rhetorical force, or exerted as much influence on the movement as a whole. . . . 
It proceeded to work its subversive path through many rooted doctrines of in-
ternational law, forever changing the discourse of international relations on is-
sues vital to human decency and peace. 
Id. at 139 (internal citation and quotation marks omitted). The UDHR was originally 
intended to give rise to a single binding convention. Id. However, due to ideological dif-
ferences, two covenants, one for civil and political rights and another for social, eco-
nomic, and cultural rights were created, id. at 242–45, even though the UDHR “included 
both categories without any sense of separateness or priority.” Id. at 247. 
 47. International Covenant on Civil and Political Rights, Dec. 16, 1966, 999 U.N.T.S. 
171, [hereinafter ICCPR], available at http://www.ohchr.org/english/law/pdf/ccpr.pdf. 
The rights secured by the ICCPR can be loosely classified into the following five: (1) 
protection of the individual’s physical integrity (e.g., prohibitions on torture and arbitrary 
deprivations of life); (2) procedural due process; (3) equal protection; (4) freedoms of 
belief, speech, and association; and (5) the right to political participation. STEINER & 
ALSTON, supra note 46, at 145. There are currently 160 state parties to the ICCPR. U.N. 
High Comm. On Hum. Rts., Status of Ratification: ICCPR, http://www2.ohchr.org 
/english/bodies/ratification/4.htm (last visited Feb. 14, 2008). 
 48. International Covenant on Economic, Social, and Cultural Rights, Dec. 16, 1966, 
993 U.N.T.S. 3, [hereinafter ICESCR], available at http://www.ohchr.org/english/law/pd 
f/cescr.pdf. 
 49. STEINER & ALSTON, supra note 46, at 136. 
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also officially established every individual’s right to health, thus making 
access to treatment for medical illness a human rights and international 
law issue. 
Article 25.1 of the UDHR proclaims that “[e]veryone has the right to a 
standard of living adequate for the health and well-being of himself and 
of his family, including food, clothing, housing and medical care and 
necessary social services.”50 This concept is comprehensively enshrined 
in and given binding effect by article 12 of the ICESCR. Section 1 of the 
article defines the right and section 2 lays out the correlative governmen-
tal obligations to protect the right by providing an “illustrative, non-
exhaustive” list of examples.51 Article 12 reads in relevant part: 
1. The States Parties to the present Covenant recognize the right of eve-
ryone to the enjoyment of the highest attainable standard of physical 
and mental health. 
2. The steps to be taken by the States Parties to the present Covenant to 
achieve the full realization of this right shall include those necessary 
for: 
 . . . 
(c) The prevention, treatment and control of epidemic, endemic, occu-
pational and other diseases; 
(d) The creation of conditions, which would assure to all medical ser-
vice and medical attention in the event of sickness.52 
The right to health is also recognized in various other international and 
regional agreements.53 None of these documents explicitly grant a right 
of “access to pharmaceuticals,” however, the language of the provisions 
                                                                                                             
 50. UDHR, supra note 46, art. 25.1. 
 51. CESCR Gen. Comment 14, supra note 22, ¶ 7. 
 52. ICESCR, supra note 48, art. 12. 
 53. See International Convention on the Elimination of All Forms of Racial Discrimi-
nation, Art. 5(e)(iv), opened for signature Mar. 7, 1966, 660 U.N.T.S. 212; Convention 
on the Elimination of All Forms of Discrimination against Women, art. 11.1(f), 12, Dec. 
18, 1979, 1249 U.N.T.S. 14; Convention on the Rights of the Child, art. 24, adopted Nov. 
20, 1989, 144 U.N.T.S. 123; The European Social Charter, art. 11, Oct. 13, 1961, 529 
U.N.T.S. 89; African Charter on Human and Peoples’ Rights, art. 16, Jan. 27, 1981, 21 
I.L.M. 58. For a collection of the basic international right to health documents, see gener-
ally FRANCIOS-XAVIER BAGNOUD CTR. FOR HEALTH AND HUM. RTS., HARV. SCH. OF PUB. 
HEALTH, HEALTH AND HUMAN RIGHTS: BASIC INTERNATIONAL DOCUMENTS (Stephen P. 
Parks ed., 2004). For a more comprehensive collection, see THE RAOUL WALLENBERG 
INSTITUTE OF HUMAN RIGHTS AND HUMANITARIAN LAW, A THEMATIC GUIDE TO 
DOCUMENTS ON HEALTH AND HUMAN RIGHTS (Gudmundur Alfredsson & Katrina 
Tomaševski eds., 1999). 
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clearly contemplates access to essential medicines and article 25 has 
been interpreted to include such a right.54 Moreover, other rights also 
imply a right of access to pharmaceuticals. The UDHR states that every-
one has the right to “share in scientific advancement and its benefits.”55 
The ICESCR confers on everyone “the right to enjoy the benefits of sci-
entific progress and its applications.”56 There is also the right to life it-
self,57 to which the right to health is regarded as “closely related” and 
“dependent upon.”58 
Finally, access to essential medicines is acknowledged as a legitimate 
and important concern in non-human rights contexts as well. The WTO 
has most prominently addressed the issue.59 The World Bank has issued 
statements recognizing its importance.60 Even the World Intellectual 
Property Organization (“WIPO”),61 which downplays both the impact of 
patent protection on drug prices and the impact of drug prices on access 
to drugs, acknowledges the importance of striking a balance between 
                                                                                                             
 54. See CESCR Gen. Comment 14, supra note 22, ¶ 11–12 (identifying access to es-
sential medicines as defined by the WTO as a core obligation of states under right to 
health and explaining that the right to health is “an inclusive right extending not only to 
the timely and appropriate health care but also to the underlying determinants of  
health” and requires states parties to ensure that health facilities, goods, and services 
“whether privately or publicly provided, are affordable for all, including socially disad-
vantaged groups”); see also Special Rapporteur’s Mission to the WTO, supra note 3, ¶ 43 
(explaining that because the right to health includes access to essential medicines, patent 
protection can infringe upon the right). 
 55. UDHR, supra note 46, art. 27(1). 
 56. ICESCR, supra note 48, art 15(1)(b). 
 57. UDHR, supra note 46, art. 3 (“Everyone has the right to life, liberty and security 
of person.”); ICCPR, supra note 47, art. 6(1) (“Every human being has the inherent right 
to life. This right shall be protected by law. No one shall be arbitrarily deprived of his 
life.”). 
 58. See CESCR Gen. Comment 14, supra note 22, ¶ 3. 
 59. See infra Part II.A. 
 60. See Juan Rovira, Trade Agreements, Intellectual Property, and the Role of the 
World Bank in Improving Access to Medicines in Developing Countries, 4 YALE J. 
HEALTH POL’Y L. & ETHICS 401 (2004), 410–411 (describing the World Bank’s position 
encouraging the use of patent flexibilities and the production of generics to increase ac-
cess to antiretroviral AIDS drugs). 
 61. WIPO is a specialized United Nations agency with a mandate “to promote the 
protection of IP throughout the world through cooperation among states and in collabora-
tion with other international organizations.” WIPO, What is WIPO?, 
http://www.wipo.int/about-wipo/en/what_is_wipo.html (last visited Feb. 14, 2008). For a 
brief overview of WIPO’s history and the WIPO framework, see Elaine Gin, Interna-
tional Copyright Law: Beyond the WIPO & TRIPS Debate, 86 J. PAT. & TRADEMARK 
OFF. SOC’Y 763 (2004), 779–781. 
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health concerns such as access to medicine and the benefits of a robust 
patent regime.62 
Despite the fact that the concept has been a part of the human rights 
movement for quite some time and is recognized in a number of instru-
ments, the right to health does not enjoy the same legal force as rights 
that are considered “fundamental,” such as rights protecting against tor-
ture and genocide. There are a number of reasons for this. First, the right 
to health suffers from a degree of “conceptual unclarity.”63 Although cer-
tain core concepts, including access to essential medicine, have emerged 
over the years,64 “[i]t is difficult to pinpoint exactly what the right to 
health contains. Health is a very broad and subjective concept . . . [and] 
there exists a certain normative overlap with other human rights . . . .”65 
Second, the right to health is different from other human rights in that 
it is subject to progressive realization over time.66 However, 
“[r]ecognition of core content underlines the fact that some elements are 
not subject to progressive realization and should be realized immediately, 
a notion which makes the right to health more tangible.”67 Additionally, 
the right to health does impose an immediate obligation to take meaning-
ful steps towards its fulfillment.68 Finally, there is a presumption that the 
                                                                                                             
 62. See WIPO, Striking a Balance: The Patent System and Access to Drugs and 
Health Care, http://www.wipo.int/freepublications/en/patents/491/wipo_pub_491.pdf 
(last visited Feb. 14, 2008) (describing the WIPO’s efforts to strike the appropriate bal-
ance between public health concerns relating to access to medicine and the interests of 
patent owners). 
 63. Brigit Toebes, The Right to Health, in ECONOMIC, SOCIAL, AND CULTURAL RIGHTS 
175 (Asbjørn Eide, Catarina Krause & Allan Rosas eds., 2d rev. ed. 2001). 
 64. Id. at 176–177. Core concepts are primarily derived from the WHO Health for All 
strategy and include maternal and child healthcare, family planning, immunization 
against the major infectious diseases, appropriate treatment of common diseases and inju-
ries, education concerning prevention and control of major health problems, promotion of 
food supply and proper nutrition, and adequate supply of safe water and basic sanitation. 
Id. 
 65. Id. at 174–175. See also John D. Blum, Is Justice for One Justice for All? The 
Dilemma of Public Health Enforcement in an Interconnected World, 36 LOY. U. CHI. L.J. 
349 (2004) (describing the difficulty of achieving an international agreement on what the 
right to health means as a function of the “conceptual split over health, and the commen-
surate legal right to health, between the developed and the developing world”). 
 66. See CESCR Gen. Comment 14, supra note 22, ¶ 31 (“[P]rogressive realization 
means that States parties have a specific and continuing obligation to move as expedi-
tiously and effectively as possible towards the full realization of article 12.”). 
 67. Toebes, supra note 63, at 176. 
 68. CESCR Gen. Comment 14, supra note 22, ¶ 30 (“States parties have immediate 
obligations in relations to the right to health, such as the guarantee that the right will be 
exercised without discrimination of any kind (art. 2.2) and the obligation to take steps 
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right prohibits states from taking steps that would undermine progress 
towards its realization69 as well as an obligation to “refrain from interfer-
ing directly or indirectly with the enjoyment” of it.70 
Another challenge is that the right to health is not universally binding. 
One hundred fifty-seven countries have ratified the ICESCR.71 Thus, five 
countries, including the United States, are not bound to its expression of 
the right to health.72 Moreover, the right to health does not enjoy the sta-
tus of customary international law,73 which would be binding on the 
United States in certain contexts despite the absence of a formal recogni-
tion of the right.74 Additionally, unlike the ICCPR, there currently is no 
formal system in place for adjudicating violations of the ICESCR.75 Fi-
                                                                                                             
(art. 2.1) towards the full realization of article 12. Such steps must be deliberate, concrete 
and targeted towards the full realization of the right to health.”). 
 69. Id. ¶ 32 (“As with all other rights in the Covenant, there is a strong presumption 
that retrogressive measures taken in relation to the right to health are not permissible. If 
any deliberately retrogressive measures are taken, the State party has the burden of prov-
ing that they have been introduced after the most careful consideration of all alternatives 
and that they are duly justified by reference to the totality of the rights provided for in the 
Covenant in the context of the full use of the State party’s maximum available re-
sources.”). 
 70. Id. ¶ 33. 
 71. Office of the United Nations High Commission for Human Rights, ICESCR Rati-
fications and Reservations, http://www2.ohchr.org/english/bodies/ratification/3.htm (last 
visited Feb. 14, 2008). 
 72. Other abstainers are Belize, Pakistan, Sao Tome and Principe, and South Africa. 
Id. All of these countries, including the United States, have signed the covenant without 
reservation but have not yet ratified it. Id. One, South Africa, has a domestic constitu-
tional right to health. S. AFR. CONST. 1996 art. 27. 
 73. Flores v. S. Peru Copper Corp., 414 F.3d 233, 254 (2d Cir. 2003) (holding that the 
right to health is “insufficiently definite to constitute rules of customary international 
law”). 
 74. For example, in the Alien Tort Claims Act (“ATCA”), which gives federal district 
courts original jurisdiction over civil actions by aliens for torts committed “in violation of 
the law of nations or a treaty of the United States.” 28 U.S.C. § 1350 (2000). In this con-
text, courts “have consistently used the term ‘customary international law’ as a synonym 
for the term the ‘law of nation.’” Flores, 414 F.3d at 237 n.2. 
 75. Article 16 of the ICESCR requires states parties to submit “reports on the meas-
ures which they have adopted and the progress made in achieving the observance of the 
rights recognized herein,” which includes the right to health, to the Commission on Eco-
nomic, Social, and Cultural Rights (“CESCR”), the body charged with overseeing the 
implementation of the ICESCR. This generally takes the form of a written and oral dis-
cussion between the CESCR and a state government that concludes with the CESCR 
adopting “concluding observations in relation to a specific state report.” Allan Rosas & 
Martin Scheinin, Implementation Mechanisms and Remedies, in ECONOMIC, SOCIAL, AND 
CULTURAL RIGHTS 426–427 (Asbjørn Eide, Catarina Krause & Allan Rosas eds., 2d rev. 
ed. 2001). This system “is more and more resembling a quasi-judicial complaint proce-
2008] ACCESS TO ESSENTIAL MEDICINES 609 
nally, many governments are ambivalent or hostile to economic and so-
cial rights generally in part because they believe civil and political rights 
are more basic and urgent and should be prioritized.76 
The fact that the right to health is a progressive right, lacks binding 
force, and struggles along with other economic and social rights to be 
taken seriously leaves individuals hoping to assert it with no venue to 
challenge general violations. However, as will be argued in Part II of this 
Note, the access to essential medicines component of the right to health 
is now ripe for elevation to customary international law. Assigning such 
status to the access issue is a step towards judicial enforcement. 
C. The Legal Dilemma: The Conflict between Intellectual Property 
Rights and Health Rights 
Another issue that complicates the realization of the right to health is 
that, like all rights, it competes and conflicts with other rights. Often, 
these other rights are more widely accepted and are supported by a much 
more robust jurisprudence consisting of generations of statutes, treaties, 
and case law.77 It is, in a sense, an uneven fight. Consequently, right to 
                                                                                                             
dure[,]” but there still is no official complaint procedure. Id. at 427. This is in contrast to 
the ICCPR (the treaty that guarantees civil and political rights, see supra note 47), which 
is authorized to receive, review, and issue opinions on complaints from individuals claim-
ing that a state has violated an ICCPR provision. See STEINER & ALSTON, supra note 46, 
at 738. This individual complaint system was made possible through the enactment of a 
binding optional protocol to the ICCPR, id., and has enabled the development of interna-
tional case law and jurisprudence on civil and political rights. See John Quigley, The 
International Covenant on Civil and Political Rights and the Supremacy Clause, 42 
DEPAUL L. REV. 1287, 1294 (1993). Efforts to enact a similar system for the ICESCR 
have been underway since 1990, but no consensus has been reached thus far. Michael J. 
Dennis & David P. Stewart, Justiciability of Economic, Social, and Cultural Rights: 
Should There be an International Complaints Mechanism to Adjudicate the Rights to 
Food, Water, Housing, and Health?, 98 AM. J. INT’L L. 462, 463 (2004). “Proponents of a 
complaints mechanism have long argued that the absence of strong enforcement mecha-
nisms in the ICESCR has marginalized economic, social, and cultural rights and stymied 
their full realization.” Id. 
 76. STEINER & ALSTON, supra note 46, at 249–51. 
 77. Cf. Asbjørn Eide & Allan Rosas, Economic, Social, and Cultural Rights: A Uni-
versal Challenge, in ECONOMIC, SOCIAL, AND CULTURAL RIGHTS at 4 (describing one 
theory advanced by many that regards civil and political rights as first generation rights 
and economic, social, and cultural rights as second generation rights); id. at 5 (“It is a 
well-known fact that economic, social, and cultural rights are surrounded by controver-
sies, both of an ideological and technical nature. To some, they are not true rights at  
all . . . .”). 
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health issues are not prioritized.78 The right to access to essential medi-
cines, in particular, is in direct competition most significantly with patent 
rights. 
Unlike the right to health, patent rights are longstanding79 and univer-
sally accepted.80 They are a component of intellectual property rights81 
and give inventors the ability to legally exclude others from profiting 
from their innovations.82 The theory of patent rights is based on the pre-
mise that inventions are “public goods that are costly to make and that 
are difficult to control once they are released into the world.”83 Thus, 
patent rights provide the economic incentive necessary to spur invention 
by giving inventors the ability to take legal action against those that at-
tempt to profit from the their invention, whether by stealing it, reverse 
engineering it, or discovering it independently.84 
Patent protection directly conflicts with access to essential medicine 
because it prevents the production and sale of generic versions of pat-
ented drugs.85 Generic drugs significantly increase the accessibility of 
                                                                                                             
 78. Cf. id. at 3 (In the years since the passage of the ICCPR and the ICESCR, “civil 
and political rights have attracted much more attention in theory and practice, while eco-
nomic, social, and cultural rights have often been neglected.”). 
 79. The history of the patent system can be traced back to the Renaissance. Id. at 106. 
Patent law first started becoming internationalized (such that an inventor with patent 
rights in one country could assert them in another country) in 1883 with the Paris Con-
vention. Id. at 293. 
 80. For example, patent protection is alluded to in article 27(2) of the UDHR, supra 
note 46. Article 15(1)(c) of the ICESCR, supra note 48, states that every person has “the 
right to benefit from the protection of the moral and material interests resulting from any 
scientific, literary or artistic production of which he is the author.” (Interestingly, this 
same article guarantees the right of everyone to benefit from scientific advancement.) In 
1893, fourteen countries formed the predecessor to the World Intellectual Property Or-
ganization (“WIPO”). WIPO, About WIPO, http://www.wipo.int/treaties/en/general/ (last 
visited Feb. 14, 2008). In 1974, WIPO became an official part of the United Nations and 
currently has 184 member countries. Id. 
 81. MERGES ET AL., supra note 12. 
 82. Id. 
 83. Id. at 119. 
 84. Id. Other theories justifying patent rights include reward-based theories, natural 
law theories, personhood theories, and property theories but these other theories play a 
less significant role in patent law. Id. at 119 & n.38. 
 85. Cf. Robert Weissman, A Long, Strange Trips: The Pharmaceutical Industry Drive 
to Harmonize Global Intellectual Property Rules, and the Remaining WTO Legal Alter-
natives Available to Third World Countries, 17 U. PA. J. INT’L ECON. L. 1069, 1099 
(1996) (“Justified even on its own terms, the patent is not an unmitigated good. . . . It 
does accomplish its stated goal of placing information regarding the newly invented item 
in the public domain, but it does so at the expense of conditioning the right to use this 
information commercially on securing a license from the patent holder. A license can 
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medicine because they are cheaper than the patented brand name ver-
sions. “It is well documented that drug prices drop when countries pro-
mote the use of generics, abolish patents, or impose direct price con-
trols.”86 
At the international level, the production of generic drugs was primar-
ily impeded by TRIPS, an agreement passed in 1994 by the WTO.87 The 
agreement “brings together . . . a broad range of intellectual property 
rights (“IRPs”) previously protected by subject-specific agreements”88 
and is “the first significant multilateral agreement requiring member 
countries to provide certain minimum levels of protection to owners of 
intellectual property.”89 It also contains an enforcement mechanism. A 
state party alleging violations of the agreement by another state party 
may have its claim adjudicated by WTO dispute settlement procedures.90 
Member states that fail to comply with the provisions of the agreement 
may be subject to trade sanctions.91 Additionally, TRIPS requires mem-
ber states to maintain both civil and criminal enforcement procedures 
within their own borders to protect individual rights holders.92 Currently, 
151 countries are members of the WTO and TRIPS.93 
Part II, section 5 of TRIPS governs patents. It sets the minimum sub-
stantive protections that all member governments must provide to eligi-
                                                                                                             
usually only be acquired for a fee and, in the case of pharmaceuticals, is often not avail-
able for any feasible price.”). 
 86. Rahul Rajkumar, Note, The Central American Free Trade Agreement: An End 
Run Around The Doha Declaration on Trips and Public Health, 15 ALB. L.J. SCI. & 
TECH. 433, 438 (2005) (citing Fredrick T. Schut & Peter A.G. Van Bergeijk, Interna-
tional Price Discrimination: The Pharmaceutical Industry, 14 WORLD DEV. 1141, 1147 
(1986)). 
 87. Supra note 14; cf. Doha Public Health Declaration, supra note 18, ¶ 3 (WTO dec-
laration issued after trade rules were hindering access to medicines and acknowledging 
the effect of intellectual property rights on prices). 
 88. Laurence R. Helfer, Adjudicating Copyright Claims Under the TRIPS Agreement: 
The Case for a European Human Rights Analogy, 39 HARV. INT’L L.J. 357, 358–59 
(1998). 
 89. Bagley, supra note 17, 782. 
 90. TRIPS, supra note 14, art. 64.1 (stating that disputes arising under TRIPS shall be 
settled by the standard WTO dispute settlement procedures established in “articles XXII 
and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Under-
standing . . .”). 
 91. Bagley, supra note 17, 782–83. 
 92. TRIPS, supra note 14, arts. 41–61. 
 93. WTO, Members and Observers, http://www.wto.org/english/thewto_e/whatis_e 
/tif_e/org6_e.htm (last visited Feb. 14, 2008). There are also thirty-two observer coun-
tries, some of which are currently in accession negotiations and all of which, excluding 
the Holy See, must begin accession negotiations within five years of becoming an ob-
server. Id. 
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ble innovations and provides criteria that tightly control the circum-
stances under which derogation of patent rights is permitted.94 Under 
article 27, pharmaceutical drugs are generally eligible for patent protec-
tion.95 However, products must be new and innovative in order to receive 
protection.96 Article 28 defines the patent holder’s rights. These include 
the right to exclude third parties from making, using, selling, or import-
ing the patented product or process without consent97 as well as the right 
to assign, transfer, and license the patent.98 Under article 33, the patent 
holder has the right to exercise these rights for a term of twenty years.99 
Article 30 allows the government of a member state to limit a patent 
holder’s right to exclude other generic manufacturers “provided that such 
exceptions do not unreasonably conflict with the normal exploitation of 
the patent and do not unreasonably prejudice the legitimate interests of 
the patent owner, taking account of the legitimate interests of third par-
ties.”100 
Under article 27, a member government is permitted to deny a patent to 
an otherwise eligible invention if preventing the commercialization of 
the invention “is necessary to protect ordre public or morality, including 
to protect human, animal or plant life or health or to avoid serious preju-
dice to the environment . . . .”101 This provision is known as the public 
health exception.102 Article 31 establishes parameters under which a 
                                                                                                             
 94. Bagley, supra note 17, at 785. 
 95. Cf. TRIPS, supra note 14, at art. 27.3 (listing the types of products that are ineli-
gible for patent protection under TRIPS as “diagnostic, therapeutic and surgical methods” 
and “plants and animals other than micro-organisms”). Although article 27 does not ex-
plicitly mention pharmaceuticals, that they were intended to receive patent protection is 
evident from article 70(8). That article is a special provision for countries that did not 
already provide patent protection for pharmaceuticals that required those countries to 
begin to do so as they transitioned into TRIPS compliance. See Peggy B. Sherman & 
Ellwood F. Oakley, III, Pandemics and Panaceas: The World Trade Organization’s Ef-
forts to Balance Pharmaceutical Patents and Access to AIDS Drugs, 41 AM. BUS. L.J. 
353, 363 (2004). The inclusion of article 70.8 was “[o]ne of the most significant victories 
in TRIPS for the pharmaceutical industry.” Id. at 364. 
 96. TRIPS, supra note 14, at art. 27.1. 
 97. TRIPS, supra note 14, at art. 28.1(a)–(b). 
 98. Id. art. 28.2. 
 99. Id. art. 33 (“The term of protection available shall not end before the expiration of 
a period of twenty years.”). 
 100. Id. art. 30. 
 101. Id. art. 27.2. 
 102. See Weissman, supra note 85, at 1099. Some have argued that article 27, which 
states that therapeutic processes are ineligible for patent protection, is also a public health 
exception because pharmaceuticals are a therapeutic process for the treatment of ill-
nesses. However, this interpretation is “extreme” and “inconsistent” with article 70.8, 
which specifically discusses the patentability of pharmaceuticals. Sherman & Oakley, 
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member government may exercise the public health exception by break-
ing a pharmaceutical drug patent, also known as compulsory licensing.103 
The decision to break a patent in this manner must be made on a case-by-
case basis.104 Additionally, the patent can only be broken for a limited 
scope and duration.105 The majority of the goods produced as a result of 
the patent break must be used domestically106 and thus they cannot be 
exported to another country.107 The member government must also pay 
the patent holder remunerations if it breaks the patent.108 
These mechanisms that allow member governments to loosen patent 
protection in cases of national emergencies are commonly referred to as 
“flexibilities.”109 The flexibilities make TRIPS compatible with an inter-
national patent system that adequately balances patent interests with the 
need for access to essential medicines. The system was able to address 
the concerns of the pharmaceutical industry110 while allowing member 
                                                                                                             
supra note 95, at 368. Public health is also mentioned in article 8.1, which states that 
“[m]embers may, in formulating or amending their laws and regulations, adopt measures 
necessary to protect public health and nutrition, and to promote the public interest in 
sectors of vital importance to their socio-economic and technological development, pro-
vided that such measures are consistent with the provisions of this Agreement.” TRIPS, 
supra note 14, art. 8.1. 
 103. Compulsory licensing allows a country to give someone other than the patent-
holder, such as a manufacturer of generic drugs, the right to manufacture and sell the 
patented product without the patent-holder’s permission. BEIGBEDER, supra note 1, at 65. 
The article makes specific reference to a “case of a national emergency or other circum-
stances of extreme urgency,” TRIPS, supra note 14, art. 31(b), however, compulsory 
licensing is also permitted for non-emergency situations such as non-commercial public 
use, id. art. 31(c), or to correct anti-competitive practices, id. art. 31(k). Additionally, 
article 30 of TRIPS “potentially provides for very broad exceptions to the patent re-
quirements of the Agreement . . . [as it] does not limit the purposes for which a country 
may make exceptions to the Agreement.” Weissman, supra note 85, at 1108. 
 104. TRIPS, supra note 14, art. 31(a). 
 105. Id. art. 31(c). 
 106. Id. art. 31(f). 
 107. Id.; see also Fact Sheet: TRIPS and Pharmaceutical Patents, supra note 19. 
 108. Id. art. 31(h). 
 109. See, e.g., Sherman & Oakley, supra note 95, at 368 (referring to provisions that 
compose the public health exception as “TRIPS flexibilities”). 
 110. Indeed, as described in Weissman, supra note 85, the American pharmaceutical 
industry aggressively and successfully sought out deference to its international interests 
both before and during the TRIPS drafting process. Through intense lobbying and politi-
cal maneuvering, it was the pharmaceutical industry that prompted the United States to 
demand that intellectual property be negotiated into the GATT. Once TRIPS negotiations 
began, the industry “completely seized control of the terms of the debate.” Id. at 1085. 
“Throughout the . . . negotiations, the United States maintained a firm stance; for an 
agreement to be reached, other countries would have to adjust to its position. That posi-
tion, essentially calling for the world to adopt U.S.-style patent law, was developed 
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governments the ability to modify their patent rules where necessary to 
secure the citizens’ right to health. 
Unfortunately, these flexibilities proved unsuccessful. Despite the in-
clusion of a public health exception in TRIPS, patent protection still pre-
vented access to essential medicine. The TRIPS flexibilities were under-
utilized because they were unclear and developing nations feared retalia-
tion from other countries if they invoked them.111 For example, when 
South Africa attempted to invoke the flexibilities for patented AIDS 
drugs, forty-two pharmaceutical companies filed suit alleging violation 
of TRIPS and the United States Trade Representative (“USTR”)112 pres-
sured the South African government to maintain normal patent protec-
tion.113   
Another problem with the public health exception was the “Paragraph 
6 Problem,” a reference to TRIPS article 31(f) (the sixth paragraph of 
article 31).114 As discussed above, article 31(f) requires that goods pro-
duced pursuant to compulsory licensing115 be used “predominantly for 
                                                                                                             
largely by the pharmaceutical industry, according to the industry itself.” Id. at 1084. For 
an excellent description of the American pharmaceutical industry’s tactics and influence 
on international patent law, both before and after TRIPS, see id. at 1075–93. 
 111. Bagley, supra note 17, at 784–85. 
 112. The office of the United States Trade Representative is an executive agency re-
sponsible for formulating and implementing U.S. trade policy. Its responsibilities include 
advising the president on international trade policy and the impact of other U.S. govern-
ment policies on international trade, conducting international trade negotiations, coordi-
nating trade policy with other agencies, and reporting to the president and Congress on 
the administration of the trade agreements program. See USTR—History of the United 
States Trade Representative, http://ustr.gov/Who_We_Are/History_of_the_United_States 
_Trade_Representative_printer.html (last visited Jan. 28, 2008). 
 113. Bagley, supra note 17, at 784–85. The lawsuit was prompted by South Africa’s 
passage of the Zuma Law in December of 1998 in the hopes of driving down drug prices 
by opening the market to generic imports. The American pharmaceutical industry, which 
at the time enjoyed a $2 billion-a-year drug market in South Africa, believed the law 
would threaten their profits and that other countries would enact similar laws. In addition 
to the law suit, some companies closed their plants in South Africa, forty-seven members 
of Congress asked the USTR to take action to oppose the law, and President Clinton met 
personally with the South African Health Minister, after whom the law was named, to 
express his administration’s opposition to it. The New York Times described the dispute 
as “bitter[] and driven by deep suspicions.” Donald G. McNeil, Jr., South Africa’s Bitter 
Pill for World’s Drug Makers, N.Y. TIMES, Mar. 29, 1998, § 3 at 1. The lawsuit was 
eventually dropped due largely to intense pressure from humanitarian nongovernmental 
organizations (“NGOs”). See BEIGBEDER, supra note 1, at 59. 
 114. See Thomas A. Haag, TRIPS Since Doha: How Far Will the WTO Go Toward 
Modifying the Terms for Compulsory Licensing?, 84 J. PAT. & TRADEMARK OFF. SOC’Y 
945, 952 (2002). 
 115. Supra note 103. 
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the domestic market.”116 The problem with this provision is that many 
countries able to efficiently to produce generic drugs117 could not export 
them to countries that needed cheaper versions but lacked the infrastruc-
ture and industry to produce them domestically.118 “Thus, for a state 
lacking a drug manufacturing base, the ability to issue a compulsory li-
cense [was] largely academic.”119 Others have argued that the language 
of TRIPS itself does not impede access as much as the power disparity 
between developed and developing nations.120 
II. LEGAL RESPONSES TO THE CONFLICT OF RIGHTS 
A. The WTO Approach 
In 2001, the African members of the WTO asked the WTO council to 
clarify the TRIPS public health exception and the extent of members’ 
rights to use it.121 The WTO agreed,122 and the clarification was an-
nounced in 2001 in the Declaration on the TRIPS Agreement and Public 
Health (“Doha Declaration”).123 “The Doha Declaration . . . explicitly 
addressed some of the most problematic TRIPS provisions from the 
standpoint of access to essential medicines, and returned a significant 
measure of freedom to member countries to provide such access to their 
citizens within the framework of the existing the TRIPS Agreement lan-
guage.” 124 
The Doha Declaration resulted in several positive steps towards har-
monizing intellectual property rights and access to essential medicine. 
First, it officially “recognized the gravity of the public health problems 
                                                                                                             
 116. TRIPS, supra note 14, art. 37(f). 
 117. These include India—which was the largest supplier of generic anti-AIDS drugs 
to the world before it ratified TRIPS, requiring it to provide patent protection to pharma-
ceuticals, Sherman & Oakley, supra note 95, at 381–82, 392—and Brazil, id. at 388. 
 118. Haag, supra note 114, at 951. 
 119. Id. The practice of importing cheaper generic versions of drugs under patent in 
one’s own country is known as parallel importing. BEIGBEDER, supra note 1, at 65. A 
detailed explanation of TRIPS, which does not explicitly address parallel importing but 
has been interpreted to disallow it, can be found in Haag, supra note 114. 
 120. See Dr. Susan K. Sell, Legal Movements in Trade & Intellectual Property, 17 
EMORY INT’L L. REV. 591, 593 (2003). 
 121. See Brook K. Baker, Arthritic Flexibilities for Accessing Medicines: Analysis of 
WTO Action Regarding Paragraph 6 of the Doha Declaration on the TRIPS Agreement 
and Public Health, 14 IND. INT’L & COMP. L. REV. 613, 623 (2004); Press Release, WTO, 
Decision Removes Final Patent Obstacle To Cheap Drug Imports (Aug. 30, 2003), avail-
able at http://www.wto.org/english/news_e/pres03_e/pr350_e.htm. 
 122. Id. 
 123. Doha Public Health Declaration, supra note 18. 
 124. Bagley, supra note 17, at 785. 
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 . . . resulting from HIV/AIDS” and “the concerns about [intellectual 
property rights’] effects on prices.”125 It also stated in unequivocal terms 
that TRIPS “does not and should not prevent members from taking 
measures to protect public health”126 and “reaffirm[ed] the right of WTO 
members to use, to the full, the provisions in the TRIPS Agreement, 
which provide flexibility for this purpose.”127 The Doha Declaration also 
clearly established the right of member governments to use compulsory 
licensing in national emergencies and to determine for themselves what 
constitutes a national emergency while also recognizing public health 
issues related to HIV/AIDS as a legitimate national emergency under the 
agreement.128 
The Doha Declaration also took concrete steps towards policy change. 
It instructed the TRIPS council to find an “expeditious solution” to the 
parallel imports problem faced by developing nations with no capacity to 
produce their own generic drugs.129 This was achieved via the 2003 Im-
plementation Decision.130 That decision created a waiver that explicitly 
allowed countries to export generic versions of essential medicines to 
countries that did not have domestic generic manufacturing capabilities 
and met certain other criteria.131 In 2005, the general council agreed on 
                                                                                                             
 125. Doha Public Health Declaration, supra note 18, ¶¶ 1, 3. 
 126. Id. ¶ 4. 
 127. Id. ¶ 4. 
 128. Id. ¶ 5(b)–(c). 
 129. Id. ¶ 6. 
 130. WTO, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS 
Agreement and Public Health, WT/L/540, 43 I.L.M. 509 (Sept. 1, 2003) [hereinafter 
2003 Implementing Decision], available at http://www.wto.org/english/tratop_e/trips_e/i 
mplem_para6_e.htm. 
 131. Id. The waiver includes several safeguards intended to prevent abuse of the sys-
tem, including a notification provision that requires countries to submit a detailed report 
of their intention to employ the flexibility, specific eligibility requirements, limits on the 
quantity of drugs that may be produced that correspond to what is needed, distinctive 
labeling requirements so that products produced under the system can be easily distin-
guished, provision requiring countries to set up administrative measures preventing unau-
thorized use and sale, and the payment of remunerations by either the importing or ex-
porting country to the patent holder. On July 17, 2007, Rwanda became the first country 
to request generic imports in response to a domestic public health crisis. Press Release, 
WTO, Patents and Health: WTO Receives First Notification Under “Paragraph 6” System 
(July 20, 2007), available at http://www.wto.org/english/news_e/news07_e/public_ 
health_july07_e.htm. On October 4, 2007, Canada notified the WTO that it planned to 
invoke the compulsory license provisions of the Doha Declaration to provide Rwanda 
with the needed medicine—260,000 packs of a generic version of TriAvir, a triple com-
bination AIDS therapy drug. Press Release, WTO, Canada is First to Notify Compulsory 
License to Export Generic Drug (Oct. 4, 2007), available at http://www.wto.org 
/english/news_e/news07_e/trips_health_notif_oct07_e.htm. 
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an amendment to TRIPS that would permanently incorporate the new 
exceptions into the agreement.132 
B. U.S. Multilateral and Bilateral FTAs 
With these new developments, an explicit acknowledgement by the 
WTO asserting its commitment to facilitate increased access to medicine 
and its demonstrated willingness to adjust patent laws in pursuit of this 
goal, the international intellectual property regime seemed to have struck 
a proper balance between the interests of patent-holders and the right to 
health. However, TRIPS and its accompanying instruments do not repre-
sent the full body of law on the matter. Currently, the United States is 
party to seventeen bilateral and regional FTAs.133 Each of these agree-
                                                                                                             
 132. WTO, Amendment of the TRIPS Agreement, WT/L/641 (Dec. 6, 2005) [hereinaf-
ter TRIPS Amendment], available at http://www.wto.org/english/tratop_e/trips_e 
/wtl641_e.htm. The amendment will become official once two-thirds of the WTO mem-
ber countries ratify it. WTO, Countries Accepting Amendment of the TRIPS Agreement, 
http://www.wto.org/english/tratop_e/trips_e/amendment_e.htm (last visited Feb. 5, 
2008). The Unites States was the first on board, ratifying it on December 18, 2005, just 
twelve days after the decision was announced. Id. As of January 2008, twelve other coun-
tries and the European Union have also ratified the amendment. Id. The waiver remains 
in effect for each of the countries that has not ratified the amendment and until they do 
so. Id. The WTO has also demonstrated its commitment to the access to essential medi-
cines concerns in other less monumental but nonetheless important ways. In 2002, the 
council issued a pair of decisions that extended the patent protection compliance deadline 
for least developed countries from 2005 to 2016. WTO, Least-Developed Country Mem-
bers—Obligations Under article 70.9 of the TRIPS Agreement with Respect to Pharma-
ceutical Products, WT/L/478 (July 8, 2002), available at http://www.wto.org/english 
/tratop_e/trips_e/art70_9_e.htm; WTO, Extension of the Transition Period under arti-
cle 66.1 of the TRIPS Agreement for Least-Developed Country Members for Certain 
Obligations with Respect to Pharmaceutical Products, IP/C/25 (June 27, 2002), available 
at http://www.wto.org/english/tratop_e/trips_e/art66_1_e.htm. On December 18, 2005, 
the members reaffirmed the importance and their approval of WTO efforts to clarify the 
relationship between TRIPS and public health. See WTO, Ministerial Declaration of 18 
December 2005, ¶ 40, WT/MIN(05)/DEC, available at http://www.wto.org/english 
/thewto_e/minist_e/min05_e/final_text_e.htm#public_health. In 2006, the WTO held 
workshops in Geneva and Mauritius aimed at training government officials on how to use 
the TRIPS public health flexibilities. WTO, Workshop Helps Officials Use Health Patent 
Flexibilities (Nov. 27, 2006), http://www.wto.org/english/news_e/news06_e/trips_wp_ 
27nov06_e.htm. 
 133. The bilateral agreements are the Colombia Trade Promotion Agreement, Peru 
Trade Promotion Agreement, Australia Free Trade Agreement, Bahrain Free Trade 
Agreement, Chile Free Trade Agreement, Central American-Dominican Republic Free 
Trade Agreement, Israel Free Trade Agreement, Jordan Free Trade Agreement, Malaysia 
Free Trade Agreement, Morocco Free Trade Agreement, Oman Free Trade Agreement, 
Panama Free Trade Agreement, Republic of Korea Free Trade Agreement, Singapore 
Free Trade Agreement, South African Customs Union Free Trade Agreement, Thailand 
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ments contains provisions governing patent protection that far exceed the 
protections offered by TRIPS.134 Hence, they are referred to as TRIPS-
plus provisions.135 
The effect of TRIPS-plus provisions in American bilateral and multi-
lateral FTAs include “limit[ing] the potential exclusions from patentabil-
ity, require[ing] the grant of patents for ‘new uses’ of known compounds, 
requir[ing] the extension of patent terms under certain conditions, pre-
vent[ing] parallel importation, limit[ing] the grounds on which compul-
sory licenses may be granted, and permit[ing] the prosecution of nonvio-
lation nullification or impairment claims.”136 U.S. trading partners, in 
particular least developed nations, routinely agree to such provisions de-
spite their detrimental effects on the accessibility of essential medicines 
because they hope that acquiescing to U.S. demands on the patent issues 
will help them gain leverage in other trade areas and that such conces-
sions will help build a friendly relationship with an important world su-
                                                                                                             
Free Trade Agreement, and the United Arab Emirates Free Trade Agreement. The re-
gional agreements are the Central American Free Trade Agreement, North American Free 
Trade Agreement, Asian-Pacific Economic Cooperation, Free Trade Area of the Ameri-
cas, and Middle East Free Trade Area Initiative. See Office of the U.S. Trade Representa-
tive, Trade Agreements, http://ustr.gov/Trade_Agreements/Section_Index.html (last vis-
ited Feb. 5, 2008). 
 134. See Frederick M. Abbott, The WTO Medicines Decision: World Pharmaceutical 
Trade and the Protection of Public Health, 99 AM. J. INT’L L. 317, 349–50 (2005) (argu-
ing that the U.S. patent provisions “restrict the use of the flexibilities under the TRIPS 
agreement”); see also Bagley, supra note 17, at 791–93 (“[C]ountries like the United 
States and member-states of the European Union . . . were independently engaging in 
negotiations to bind several developing countries to even higher levels of protection of 
intellectual property rights (IPRs) via bilateral agreements.”). 
 135. Bagley, supra note 17, at 793. 
 136. Abbott, supra note 134, at 350. Some of the specific TRIPS-plus provisions in-
cluded in U.S. FTAs include restricting compulsory licenses to public manufacturers 
only, thereby taking this WTO endorsed flexibility away from governments that do not 
have the capacity to publicly manufacture generics; prohibiting parallel imports, contrary 
to the 2005 WTO decision to make the waiver permanent; increasing patents terms by 
requiring an offset for delays that would result from the partner country’s marketing ap-
proval process; heightening the penalties for patent violations; prohibiting the partner 
country from giving marketing approval to a generic drug until after the brand name 
company’s patent expires, thus delaying delivery of cheaper generics to the market; and 
requiring partner countries to keep the test data for a patented drug secret for the first five 
years of the patent term, thus preventing the use of TRIPS flexibilities for the first five 
years of a patent and further delaying the availability cheap generics to patients. See Hu-
man Rights Watch, The FTAA, Access to HIV/AIDS Treatment, http://www.hrw.org 
/press/2002/10/ftaa1029-bck.htm (last visited Feb. 6, 2008). 
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perpower.137 Thus far, the United States has declined to adjust its patent 
policy to conform to the international standard.138 
As a result of this policy, American FTAs upset the balance between 
the right to health and intellectual property rights struck by the WTO. In 
turn, essential antiretroviral drug therapies for HIV/AIDS remain pro-
hibitively expensive in many countries and people in need of treatment 
do not have the access to medicine that the right to health guarantees. 
One way to regain the balance so that the patent flexibilities devised by 
the WTO can retain their effectiveness is to force a change in U.S. pol-
icy. Until recently, there was no effective legal mechanism for prompting 
such change. The Unites States was not bound by the right to health 
guaranteed by the International Bill of Rights139 and TRIPS, as initially 
adopted, establishes only a minimum level of patent protection that par-
ties are free to enhance as long as they did not contravene the thrust of 
the agreement.140 However, as Part III argues, the access to essential me-
dicines issue can now be given legal force in ways that were unavailable 
before. 
III. THE CHANGING LEGAL LANDSCAPE 
Widespread international acceptance of access to essential medicines 
as a priority health issue and the 2005 WTO decision to make the Public 
Health Waiver permanent by amending TRIPS have two consequences 
that will require the United States to change its policy on pharmaceutical 
patents. First, these developments enable the access to essential medi-
cines component of the right to health to acquire international customary 
law status, thereby giving it binding force. Second, if the TRIPS amend-
ment is ratified, it will potentially make TRIPS-plus provisions illegal 
and thus subject the United States, as a GATT signatory, to review by the 
WTO dispute settlement process. 
                                                                                                             
 137. Abbott, supra note 134, at 353–54. 
 138. In response to assertions that its patent policy detrimentally curtails TRIPS flexi-
bilities, the USTR issued side letters asserting that they do not undermine the right of 
governments to take action for the public health. However, of the various agreements that 
the USTR has negotiated, the side letters only address three agreements, the Central 
American Free Trade Agreement, the U.S.-Bahrain Free Trade Agreement, and the U.S.-
Morocco Free Trade Agreement. Id. at 352. Additionally, “they are drafted in a substan-
tially more restrictive way than the [WTO] texts” and “the USTR has questioned whether 
the understanding will have legal effect.” Id. 
 139. See supra Part I.B 
 140. See Bagley, supra note 17, at 792 (“The TRIPS Agreement specifies minimum 
levels of protection members must afford to IPRs, but explicitly allows members to im-
plement ‘more extensive protection’ as long as it does not contravene the Agreement.”). 
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A. Access to Essential Medicines as a Matter of Customary International 
Law 
It is long-standing and well-established that the United States is bound 
by international law.141 This includes customary international law142 or 
“the law of nations.”143 Customary international law consists of (1) “a 
general and consistent practice of states” that is (2) “followed by them 
from a sense of legal obligation” or opinio juris.144 In the context of hu-
man rights, the issue of customary international law has been most prom-
inently brought to U.S. courts via claims seeking relief through the Alien 
Tort Claims Act (“ATCA”).145 However, case law regarding customary 
                                                                                                             
 141. See, e.g., Sosa v. Alvarez-Machain, 542 U.S. 692, 729–30 (2004) (“For two cen-
turies we have affirmed that the domestic law of the United States recognizes the law of 
nations”); The Paquete Habana, 175 U.S. 677, 700 (1900) (“International law is part of 
our law, and must be ascertained and administered by the courts of justice of appropriate 
jurisdiction, as often as questions of right depending upon it are duly presented for their 
determination.”); RESTATEMENT (THIRD) OF THE FOREIGN RELATIONS LAW OF THE UNITED 
STATES § 111(a) (1987) [hereinafter RESTATEMENT OF FOREIGN RELATIONS LAW] (“Inter-
national law and international agreements of the United States are law of the United 
States and supreme over the law of the several States.”). International law “consists of 
rules and principles of general application dealing with the conduct of states and of inter-
national organizations and with their relations inter se, as well as with some of their rela-
tions with persons, whether natural or juridical.” RESTATEMENT OF FOREIGN RELATIONS 
LAW, supra, § 101. Though international treaties are also a part of U.S law, the fact that 
the United States is party to treaty concerning the right to health, namely TRIPS, is insuf-
ficient to a bind it in this case because under U.S. law, international treaties are non-self-
executing and thus do not in themselves impose obligations on the United States until 
separate legislation is passed. Cf. Sosa, 542 U.S. at 735. For a contrary view asserting 
that customary international law is not binding on the United States, see generally Curtis 
A. Bradley & Jack L. Goldsmith, Customary International Law as Federal Common 
Law: A Critique of the Modern Position, 110 HARV. L. REV. 815 (1997) (arguing in re-
sponse to the RESTATEMENT OF FOREIGN RELATIONS LAW that because the decision in 
Erie R.R. v. Tompkins, 304 U.S. 64 (1938), eliminated federal common law, customary 
international law is not binding). 
 142. RESTATEMENT OF FOREIGN RELATIONS LAW, supra note 141, § 102. International 
law can also be formed by “(b) international agreement; or (c) by derivation from general 
principles common to the major legal systems of the world.” Id. 
 143. Flores v. S. Peru Copper Corp., 414 F.3d 233, 377 n.2 (2d Cir. 2003) (“In the 
context of the ATCA, we have consistently used the term ‘customary international law’ 
as a synonym for the term the ‘law of nations.’”) (citing Kadic v. Karadzic, 70 F.3d 232, 
239 (2d Cir. 1995) and Filartiga v. Pena-Irala, 630 F.2d 876, 884 (2d Cir. 1980)). 
 144. RESTATEMENT FOREIGN RELATIONS, supra note 141, § 102(2). 
 145. 28 U.S.C. § 1350 (2000). The ATCA, which was passed in 1789, states in full that 
“[t]he district courts shall have original jurisdiction of any civil action by an alien for a 
tort only, committed in violation of the law of nations or a treaty of the United States.” Id. 
The viability of an ATCA claim for a health rights violation is beyond the scope of this 
Note. However, in order for courts to review the viability of a claim under the ATCA, 
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international law in general is sparse. The leading case is Sosa v. Alva-
rez-Manchain,146 an ATCA claim for relief alleging arbitrary detention as 
a violation of customary norms. In Sosa, the Supreme Court affirmed the 
view that new norms of customary international law are judicially cogni-
zable.147 While the Court recognized that it had “no congressional man-
date to seek out and define new and debatable violations of the law of 
nations,”148 it held that “the door [to independent judicial recognition of 
international norms] is still ajar subject to vigilant doorkeeping, and thus 
open to a narrow class of international norms today.”149 
In Sosa, the Court held that at least where the ATCA is concerned “any 
claim based on the present-day law of nations [must] rest on a norm of 
international character accepted by the civilized world and defined with a 
specificity comparable to the features of the 18th-century paradigms” 
that were already established at the time the ATCA was enacted.150 
While the ATCA is not directly implicated here in the essential medi-
cines context, review of that case law is appropriate as it is the only area 
that has led to any modern analysis of the mechanics of customary inter-
national law, especially with regard to the subset of international law, 
human rights, at issue here. In determining whether a practice or rule 
constitutes customary international law, courts may look to judgments 
and opinions of national and international tribunals, scholarly works, and 
unchallenged “pronouncements of states that undertake to state a rule of 
international law.”151 Thus general acceptance and opinio juris serve as 
the touchstones of international customary law while specificity enables 
such a norm to develop into a private right of action that can be pursued 
                                                                                                             
they had to discuss the issue of customary international law, as that is one of the statute’s 
three main elements. Therefore, a discussion of the ATCA cases is particularly relevant 
to the central thesis of this Note (that access to essential medicines is a binding right es-
tablished by customary international law). Indeed, they are necessary as the overwhelm-
ing bulk of U.S. jurisprudence regarding customary international law was developed by 
the ATCA cases. 
 146. 542 U.S. 692 (2004). 
 147. As pointed out by the Sosa Court, this view also bears congressional support. Id. 
at 728. The majority opinion notes that the Torture Victim Protections Act provides a 
mandate to define new violations of international law related to torture and that “the leg-
islative history includes the remark that [the ATCA] should remain intact to permit suits 
based on other norms that already exist or may ripen in the future into rules of customary 
international law though congress as a body has done nothing to promote such suits.” Id. 
(internal quotations and citations omitted). 
 148. Id. 
 149. Id. at 729. 
 150. Id. at 725. The eighteenth century norms identified by the Court were violation of 
safe conduct, infringement of the rights of ambassadors, and piracy. Id. at 724. 
 151. RESTATEMENT OF FOREIGN RELATIONS LAW, supra note 141, § 103(d). 
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under the ATCA. While the right to health in general is still evolving 
towards these levels,152 the access to essential medicines component of 
that right at least has arrived as a norm of customary international law. 
However, though access to medicines is quite specific it is unlikely that 
U.S. courts would recognize it as providing a private right of action justi-
ciable under the ATCA. 
1. General Acceptance 
The first requirement for elevation to customary international law is 
that the norm be generally accepted and practiced among the states. 
“Practice . . . includes diplomatic acts and instructions as well as public 
measures and other governmental acts and official statements of policy, 
whether they are unilateral or undertaken in cooperation with other states 
. . . . The practice necessary to create customary law may be of compara-
tively short duration . . . . A practice can be general even if it is not uni-
versally followed . . . .”153 To establish that prohibition of arbitrary deten-
tion was a customary norm, the plaintiff in Sosa relied on “a survey of 
national constitutions, . . . a case from the International Court of Justice, 
United States v Iran, 1980 I. C. J. 3, 42; and some authority drawn from 
the federal courts.”154 The Court held that these authorities were insuffi-
cient to establish a customary norm not because they were inappropriate 
proof of the standard but rather because the consensus they demonstrated 
was at too general a level to meet the standard.155 In reaching this conclu-
sion, the Court emphasized that there may be a norm against prolonged 
arbitrary detention, but the plaintiff in Sosa was only detained for one 
day.156 The Court rejected the ICJ case because it was decided on differ-
ent grounds and did not deal directly with arbitrary detention.157 Like the 
norm against arbitrary detention, the right of access to medicine is widely 
recognized by the international community. However, it does not suffer 
from the generality that was fatal to the plaintiff’s claim in Sosa. 
First, through General Comment 14, the right of access to medicine has 
been specifically adopted as a part of the ICESCR, which is binding in-
ternational law for 157 countries. Since the ICESCR was established, the 
international community’s commitment to honor the right of access to 
                                                                                                             
 152. This is especially true given that the content and definition of the right to health 
are still being developed and the right still operates as a progressive right, as discussed 
supra Part I.B. 
 153. RESTATEMENT OF FOREIGN RELATIONS, supra note 141, § 102 cmt. b. 
 154. Sosa, 542 U.S. at 737 n.27 (internal citations omitted). 
 155. Id. 
 156. Id. at 738. 
 157. Id. at 737 n.27 
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essential medicines has been reaffirmed again and again. Major United 
Nations initiatives have been launched to make access to essential medi-
cines a factual reality.158 The 193 member countries of the World Health 
Organization have made essential medicines a policy priority for that 
organization. The WTO, with its 193 member countries, has taken sev-
eral active steps in the last decade to ensure a legal regime conducive to 
realization of the right for all. This has culminated in the unprecedented 
2005 decision to amend TRIPS for the first time in the agreement’s his-
tory. Even though the amendment has not yet been ratified by the two-
thirds of member governments necessary to make it an official part of 
TRIPS, it was approved by the WTO General Council, which is the main 
decision-making body and has representatives for every member coun-
try.159 Thus, it serves as an official statement of 193 members of the 
world community that the right of access to essential medicines must be 
protected. Additionally, more so than other such statements, such as the 
ICESCR itself, this decision is a powerful statement of state practice be-
cause it takes a very specific and concrete position on the issue and was 
the product of deliberation and negotiation. 
In addition to international level commitment, several countries have 
unilaterally prioritized the issue, both has a matter of law and fact. By the 
end of 1999, over 100 countries had a national drug policy, which by 
definition includes access to essential medicine as a core objective.160 
The issue has also been successfully litigated fifty-nine times between 
1992 and 2003 in domestic courts.161 In 2000, President Bill Clinton is-
sued Executive Order 13155, in which he recognized the importance of 
access to essential medicines as dealt with in TRIPS and affirmed the 
United States’ commitment to enabling increased access in sub-Saharan 
Africa.162 
                                                                                                             
 158. See, e.g., 3 by 5 Report, supra note 6; The United Nations Millennium Develop-
ment Goals, http://www.un.org/millenniumgoals/goals.html (last visited Feb. 24, 2008); 
The Special Rapporteur’s Mission to the WTO, supra note 3. 
 159. WHO, The WTO General Council, http://www.wto.org/english/thewto_e/gcounc_ 
e/gcounc_e.htm (last visited Feb. 14, 2008). 
 160. WHO, How to Develop and Implement a National Drug Policy (2003), 
http://www.who.int/medicines/publications/policyperspectives/PPM_No6-6pg-en.pdf 
(last visited Feb. 14, 2008). 
 161. Hans V. Hogerzeil, et. al., Is Access to Essential Medicines as Part of the Fulfill-
ment of the Right to Health Enforceable though the Courts?, 368 THE LANCET 305, 305 
(2006) (presenting the results of a study that examined domestic litigation of the access to 
essential medicines component of the right to health). 
 162. Exec. Order No. 13155, 65 Fed. Reg. 30,521 (May 10, 2000). The Order used 
muted language, never mentioned the word “patent,” and emphasized that access was 
only one and not the most important issue in the fight against HIV/AIDS but it nonethe-
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Second, unlike arbitrary detention in the Sosa case, access to essential 
medicines is a very specific and narrowly defined norm. It is based on 
the concept of essential medicines as developed by the World Health Or-
ganization, which the ICESCR and the WTO have both adopted. Thus it 
applies to a very specific and finite list of pharmaceuticals. While it en-
compasses more than drug affordability, cost is a key component among 
all of the international organizations that address the right to health and 
access as well as the countries that have domestic policies regarding 
health. 
2. Opinio Juris 
“For a practice of states to become a rule of customary international 
law it must appear that the states follow the practice from a sense of legal 
obligation (opinio juris sive necessitatis); a practice that is generally fol-
lowed but which states feel legally free to disregard does not contribute 
to customary law.” At the same time, departures from the practices do 
not invalidate it as a customary norm. The Sosa Court did not address 
opinio juris and very few lower courts have had occasion to apply it.163 
In Kane v. Winn, the Court accepted the existence of international trea-
ties and non-treaty instruments such as the UDHR as evidence of opinio 
juris for a torture claim under the ATCA.164 The Court reached a similar 
conclusion in Lareau v. Manson, a prisoners’ rights case ultimately de-
cided under domestic law.165 
Several aspects of the development of the right to access to essential 
medicines demonstrate that it is followed from a sense of legal obliga-
tion. As established above, access to medicine is an essential component 
                                                                                                             
less recognized the “right” of countries to promote public health and the United States’ 
commitment to make sure its policies did not interfere with that right. Additionally, the 
Order was entitled “Access to HIV/AIDS Pharmaceuticals and Medical Technologies.” 
However, it specifically stated that it did not create any substantive or procedural rights 
enforceable against the United States as it was “intended only to improve the internal 
management of the executive branch.” Id. 
 163. The relevant cases include: Buell v. Mitchell, 274 F.3d 337 (6th Cir. 2001); Viet-
nam Ass’n for Victims of Agent Orange/Dioxin v. Dow Chemical Co. (In re Agent Or-
ange Prod. Liab. Litig.), 373 F. Supp. 2d 7 (S.D.N.Y. 2005); Kane v. Winn, 319 F. Supp. 
2d 162 (D. Mass. 2004); Aldana v. Fresh Del Monte Produce, Inc., 305 F. Supp. 2d 1285 
(S.D. Fla. 2003) vacated in part by, Aldana v. Del Monte Fresh Produce, N.A., Inc., 416 
F.3d 1242 (11th Cir. 2005); Sarei v. Rio Tinto Plc, 221 F. Supp. 2d 1116 (C.D.Cal. 2002) 
rev’d on other grounds by Sarei v. Rio Tinto PLC, 221 F. Supp. 2d 1116, (9th Cir. 2005); 
Mehinovic v. Vuckovic, 198 F. Supp. 2d 1322 (N.D. Ga. 2002); Lareau v. Manson, 507 
F. Supp. 1177 (D. Conn. 1980). 
 164. Kane, 319 F. Supp. 2d at 197. 
 165. Lareau, 507 F. Supp. at 1193 n.18. 
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of the right to health. The right to health in turn is a firmly established 
human right. A human right by definition imposes a legal obligation on 
states. It is a limit upon state action that stems from the humanity all in-
dividuals are born with and thus precedes the existence of the state. As in 
Kane and Lareau, the right is expressed in various treaties and in the 
UDHR, which U.S. courts have acknowledged as legitimate evidence of 
opinio juris. The language of legal obligation is also present in the WTO 
statements and the Executive Order 13155 concerning access to medi-
cine. Both refer to the “right” of states to promote public health. The 
WTO documents go even further and refer to the right of nations to pro-
mote access to essential medicines. Finally, the most powerful evidence 
that states are compelled to protect the right of access to essential medi-
cines is the 2005 decision to amend TRIPS.166 One hundred ninety-three 
nations agreed that the international trading regime, an aspect of law fa-
cially unrelated to health or human rights and a pillar of international 
relations, needed to be changed in order to eliminate conflicts with the 
human rights obligations of developing nations to their people. 
That the language used by the international community to express the 
concept is one step removed from the direct assertion that individuals 
have a legal right of access to essential medicines does not undermine the 
opinio juris claim. The phrase “the right of countries to promote access 
to essential medicines” would be meaningless if it did not a fortiori mean 
that the people have a corresponding right of access to essential medi-
cines. It only makes sense if read to mean that the states have a right to 
fulfill their duty to their people. The opinio juris aspect of the right of 
access to essential medicines is also not undermined by the fact that the 
issue is often discussed in terms of a practical need to respond to the 
AIDS epidemic. The law does not require that a norm be followed exclu-
sively out of a sense of legal obligation to qualify as a matter of interna-
tional customary law. For example, the prohibition against torture, which 
has been accepted as customary norm167 is similarly followed out of a 
sense of legal as well as moral obligation.168 
                                                                                                             
 166. Practice and opinio juris can be proven by the same evidence. Cf. Kane, 319 F. 
Supp. 2d at 197 (holding that the treaties relevant to the case “constitute both state prac-
tice and evidence of opinio juris”). 
 167. Filartiga v. Pena-Irala, 630 F.2d 876 (2d Cir. 1980). 
 168. Cf. Filartiga, 630 F.2d at 890 (“In the modern age, humanitarian and practical 
considerations have combined to lead the nations of the world to recognize that respect 
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B. The Impact of the TRIPS Amendment on U.S. TRIPS-Plus Policy 
Prior to the WTO’s 2005 decision to amend TRIPS, the flexibilities in-
corporated in it represented minimum protections for intellectual prop-
erty rights. Thus, the United States and other countries were free to insti-
tute more stringent protection, which by necessary implication would 
undermine the right of access, without violating the agreement. The 
amendment, if ratified, has the potential to turn the WTO patent regime 
on its head with respect to pharmaceuticals. That is, it could be inter-
preted as a ceiling above which member governments may not increase 
pharmaceutical patent protection. This in turn could mean that govern-
ments that institute patent policies that exceed the TRIPS ceiling, i.e., 
TRIP-plus polices, could be violating TRIPS and be subject to sanction. 
Whether this will occur is, of course, contingent on the amendment be-
coming official and how the amendment will be interpreted. 
To become official, the amendment must be ratified by two-thirds of 
the WTO members.169 This will likely occur without incident. It was al-
ready approved by the WTO council, which consists of representatives 
from each member country.170 Additionally, access to essential medicines 
is not a controversial issue. As discussed above, it already enjoys wide-
spread acceptance. Moreover, given the international shame brought 
upon pharmaceutical companies that attempted to sue South Africa for 
invoking TRIPS flexibilities,171 it is unlikely that any government would 
take the public relations risk of opposing the amendment. Finally, the 
country wielding the most power in the debate and the one that would be 
expected to put up the most opposition given the trade policies it negoti-
ates outside the WTO, the United States, has already ratified the amend-
ment.172 
Whether the amendment will be interpreted as a prohibition on TRIPS-
plus is much less certain. Of course, the fact that the biggest proponent of 
TRIPS-plus has ratified the treaty cuts against such a reading. Addition-
ally, despite the reports of scholars and NGOs identifying the detrimental 
effects of TRIPS-plus that are cited throughout this Note, the WTO’s 
latest review of U.S. trade policy barely mentions pharmaceutical patents 
in its over two hundred pages.173 The report was issued in 2006, well af-
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ter the adoption of the TRIPS flexibility waiver and the decision to make 
the waiver permanent via amendment. Thus it appears that the WTO was 
either unwilling or uninterested in addressing TRIPS-plus so far as multi-
lateral and bilateral FTAs were concerned. However, there are factors 
that suggest this could change once the amendment becomes official. 
First, the language of the amendment is much stronger than the original 
TRIPS-flexibilities. It expressly forbids reservations to the new protocols 
without the consent of other members.174 It states unequivocally that the 
obligations of the patent section of TRIPS that limit parallel imports 
“shall not apply” to countries that face a health crisis.175 It also forbids 
members from challenging a country that invokes a flexibility.176 Under-
lying all of these provisions, and expressed in various WTO statements, 
is the WTO’s express commitment to promoting a world trade regime 
that is in harmony with the right of access. It can be argued that all of 
this language taken together means that by pushing for TRIPS-plus, the 
United States and its trading partners are “violating a commitment [they 
have] made in the WTO”177 or that while it may “not involve a violation 
of obligations under a covered agreement . . . nevertheless . . . benefits 
are being nullified or impaired.”178 
Second, the WTO undertook to reevaluate TRIPS flexibilities and ul-
timately to adopt an amendment to strengthen them in response to a for-
mal request from its least developed member nations.179 The amendment 
is designed to eliminate the legal ambiguities resulting from the intersec-
tion of intellectual property and the right to health that prompted these 
nations to seek clarification. Thus, it can be further argued that interpret-
ing the amendment in any manner other than as categorically prohibiting 
TRIPS-plus defeats its very purpose and its reason for being. 
CONCLUSION 
Despite the international prioritization of health issues, adequate access 
to essential medicines continues to elude millions across the globe. One 
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major obstacle has been international trade and intellectual property 
laws. While significant strides have been made in harmonizing those re-
gimes with the right of access to essential medicines, U.S. TRIPS-plus 
policy thwarts progress. Until recently, there were no legal mechanisms 
to prompt the United States and its trading partners to honor the right. 
However, the WTO’s recent decision to amend TRIPS heralds new pos-
sibilities for enforcing countries’ legal obligations under the right of ac-
cess to medicine. 
That the right can now properly be considered a norm of international 
customary law is immensely significant because as such, it is universally 
binding regardless of a country’s formal acceptance of the ICESCR and 
comparable instruments. Thus, in continuing to push TRIPS-plus trade 
provisions, the United States is violating the law. While there is no spe-
cific manner in which the United States can be sanctioned, it should be 
enough that by continuing to pursue TRIPS-plus in the face of specific, 
narrowly defined, and widely accepted international standards, the 
“[g]overnment itself would become a lawbreaker.”180 
If that is not enough, however, the TRIPS amendment, once ratified, 
has the potential to force a reversal of TRIPS-plus policy by declaring it 
a violation of the GATT and by imposing sanctions on countries that 
pursue policies that undermine TRIPS flexibilities. The United States is 
powerful and there surely is a general reluctance among the other nations 
of the world to subject such an indispensable ally to trade sanctions. 
However, if the WTO is sincere about its commitment to securing the 
right of access to essential medicines, it will encourage member states to 
hold the United States accountable and will support them when they do. 
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